8th June 2022|News

OptiBiotix builds on its leading microbiome presence after floating ProBiotix Health subsidiary on AQSE Growth Market

OptiBiotix Health Plc (‘OptiBiotix’), which specialises in developing scientifically and clinically proven functional ingredients, supplements, and medical devices that modulate the microbiome to improve health and wellbeing, is continuing to build its presence in multiple areas of microbiome health following admission of its subsidiary, ProBiotix Health, to trading on the Aquis Stock Exchange in London. 

The company has developed technology platforms in multiple areas of the microbiome space including probiotics, prebiotics, synbiotics, and skin health. Products are developed based on an understanding of the mechanism of action, clinical studies to show safety and efficacy, and protected by a large IP portfolio. With over 25 publications, many authored by key opinion leaders, nearly one hundred patents, products winning multiple industry awards, and partnership deals with major corporates, OptiBiotix is increasingly being recognised as an industry leader in global microbiome industry reports. 

Stephen O’Hara, CEO of OptiBiotix commented: “As customers demand products with substantiated science, clinical studies, and health claims to support the use of functional ingredients, we are leading from the front to ensure our extensive portfolio of patents and trademarks are underpinned by strong science and clinical studies to ensure product safety and efficacy.” 

OptiBiotix develops products which prevent, manage or treat several of today’s major health challenges, including obesity, diabetes, cardiovascular disease, cognitive health, and skin conditions like psoriasis and eczema. Its products include:  

  1. SlimBiome®: a functional ingredient and CE marked medical device that reduces hunger and food cravings, thereby reducing snacking and portion size, creating sustainable weight loss 
  1. LeanBiome®: a functional ingredient that helps to reduce body fat and promote a lean athletic body composition 
  1. SweetBiotix®: a portfolio of low calorie, low glycaemic index, sweet dietary fibres with prebiotic functionality to replace sugar in food and beverages 
  1. Microbiome Modulators: novel prebiotics that selectively enhance the growth of specific microbial species and their bioactive metabolites, allowing you to precision engineer the composition of the gut microbiome 
  1. LPLDL®: a cholesterol reducing probiotic selected from over 4000 strains, which has been shown in human studies to reduce total cholesterol by 35%, LDL cholesterol by 27%, and Apolipoprotein B by 29% 

The company commercialises its products through its prebiotic and probiotic subsidiaries, which have shown doubling sales after striking deals with groups like Alfa Sigma, Actial Pharma, Apollo Hospitals, Nahdi Medical, and retail groups like Holland and Barrett and The Hut Group.    

At the end of March, OptiBiotix successfully floated its wholly owned probiotic subsidiary, ProBiotix Health plc, as a separate company to maximise its growth potential. This followed on from the public listing of its skin health subsidiary SkinBioTherapeutics in 2017, as part of a strategy to build a presence in multiple areas of the microbiome. 

O’Hara continued: “With the global probiotics market estimated to be valued at USD 61.1 billion in 2021 and projected to reach USD 91.1 billion by 2026, OptiBiotix is well placed to take advantage of consumer-driven demand towards preventative healthcare that is safe, effective and backed by strong science. This admission for ProBiotix Health onto the AQSE market represents a landmark moment – not just for us, but to aid the industry’s growth in microbiome-based science.”  

The UK-based company’s product portfolio is supported by several industry-recognised award wins, including those from NutraIngredients Europe and Asia, alongside Nutrition Industry Executive in the USA.  

O’Hara added: “With multiple award wins and agreements with global partners in place, including large retail customers like The Hut Group, Holland and Barrett, and Apollo Hospitals, OptiBiotix and ProBiotix Health are best placed to help brands that are looking to commercialise products with proven scientific and clinical studies in areas of unmet need.” 

To find out more about OptiBiotix and its activities, please visit optibiotix.com